BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 38592711)

  • 1. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
    Yan S; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Wilson M
    J Med Econ; 2024; 27(1):758-765. PubMed ID: 38708771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etranacogene Dezaparvovec: First Approval.
    Heo YA
    Drugs; 2023 Mar; 83(4):347-352. PubMed ID: 36802324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec.
    Anguela XM; High KA
    Blood Adv; 2024 Apr; 8(7):1796-1803. PubMed ID: 38592711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
    Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
    Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
    Sekayan T; Simmons DH; von Drygalski A
    Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
    Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
    Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B.
    Schmidt M; Foster GR; Coppens M; Thomsen H; Dolmetsch R; Heijink L; Monahan PE; Pipe SW
    Blood Adv; 2023 Sep; 7(17):4966-4969. PubMed ID: 37352263
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
    Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
    N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
    Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
    N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
    von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
    Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for hemophilia.
    Nathwani AC
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):569-578. PubMed ID: 36485127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
    Chowdary P; Shapiro S; Makris M; Evans G; Boyce S; Talks K; Dolan G; Reiss U; Phillips M; Riddell A; Peralta MR; Quaye M; Patch DW; Tuddenham E; Dane A; Watissée M; Long A; Nathwani A
    N Engl J Med; 2022 Jul; 387(3):237-247. PubMed ID: 35857660
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.